Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Organisation › Details

Noile-Immune Biotech Inc. (JP)

Noile-Immune Biotech, Inc., based in Tokyo, Japan, is a biotechnology company focused on the development and commercialization of novel cancer immunotherapy products to eradicate cancer cells. The Company’s goal is to discover and develop innovative cancer immunotherapies through partnerships with experts in industry and academia, including Yamaguchi University and The National Cancer Center (NCC) in Japan. *

 

Period Start 2015-04-16 established
Products Industry CAR-T technology (Chimeric Antigen Receptor T-Cell technology)
  Industry 2 oncology
Persons Person Ishizaki, Hidenobu (Noile-Immune 201908 CEO)
  Person 2 Tokashiki, Tsutom (Noile-Immune 201908 SVP Business)
     
Region Region Tokyo
  Country Japan
  Street 2-12-10 Shiba-Daimon
Minato-ku
  City 105-0012 Tokyo
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Adaptimmune Therapeutics plc. (8/27/19). "Press Release: Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products Expressing IL-7 and CCL19 as a Next-generation Treatment for Cancer Patients". Philadeliphia, PA & Oxfordshire.
     
   
Record changed: 2019-08-27

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Noile-Immune Biotech Inc. (JP)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC A October 650x80px




» top